Fresenius Medical Care North America

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Fresenius Medical Care North America sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 1 currently recruiting 10 completed later-stage tilt top decile by trial count

Fresenius Medical Care North America: 13 sponsored US clinical trials, 1 recruiting.

Fresenius Medical Care North America sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 10 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is End Stage Renal Disease, with 3 trials.

Top-decile sponsor footprint

Fresenius Medical Care North America ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

10 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 3

SAfety of Regional Citrate Anticoagulation (SARCA Study)

NCT05339139
COMPLETED NA

Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™

NCT04511338
COMPLETED NA

Fresenius Noninvasive Blood Pressure Validation

NCT04573595
COMPLETED NA

Clinical Study to Assess the Performance of the Dialyzer With Endexo™

NCT03536663
COMPLETED NA

Acid-Base Composition With Use of hemoDialysates

NCT02334267
COMPLETED Phase 4

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

NCT01427907
COMPLETED Phase 4

Phosphate Kinetic Modeling 2

NCT01252771
TERMINATED Phase 2

A Safety Study of Pentoxifylline for the Treatment of Anemia

NCT01102218
COMPLETED NA

Phosphate Kinetic Modeling

NCT01003223
COMPLETED Phase 1

Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers

NCT00742820
TERMINATED NA

ProStat Supplementation in Dialysis Patients

NCT00435123
COMPLETED

Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers

NCT00440908
COMPLETED Phase 4

Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

NCT00294866

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 1
Phase 4 3

Therapeutic Areas

End Stage Renal Disease 3
Hyperphosphatemia 2
ESRD 2
Acute Kidney Injury 1
Blood Pressure 1
Inflammation 1

Where Fresenius Medical Care North America enrollment is open (later-stage tilt)

1 recruiting of 13 indexed (8% open); 10 completed (77%).

Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: End Stage Renal Disease (3 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Fresenius Medical Care North America: open-pipeline peers nationwide

Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Fresenius Medical Care North America sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%2%4%6%8%10% Total trials Recruiting share Fresenius Medical Care North AmericaAdaptimmuneAgennixAkili Interactive LabsAlumisAndrei IagaruBioXcel TherapeuticsCorporal Michael J. Crescenz VA Medical CenterLG Chem
Fresenius Medical Care North America sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Fresenius Medical Care North America sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Fresenius Medical Care North America page

13 registered trials is a research-attention snapshot, not an endorsement of Fresenius Medical Care North America or any single study.

  • 1 of Fresenius Medical Care North America's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • End Stage Renal Disease is the condition Fresenius Medical Care North America studies most, compare against other sponsors active in the same condition before evaluating a specific study. See End Stage Renal Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Fresenius Medical Care North America pipeline card: 13 registered trials from official public datasets.Report a data error.